99
Participants
Start Date
December 31, 2012
Primary Completion Date
April 30, 2015
Study Completion Date
April 30, 2015
Bitopertin
Bitopertin once daily orally.
Placebo
Placebo matched to bitopertin once daily orally.
SSRI
Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
Medical Research Group of Central Florida, Orange City
Mount Sinai School of Medicine; Department of Psychiatry, New York
Medical Research Network - New York, New York
Finger Lakes Clinical Research, Rochester
Keystone Clinical Studies, LLC, Norristown
iResearch Atlanta, Decatur
Carman Research, Smyrna
University of South Florida, St. Petersburg
Compass Research North, LLC, Leesburg
Clinical Neuroscience Solutions,Inc, Memphis
Precise Research Centers, Flowood
North Star Research, Middleburg Heights
Dean Foundation, Middleton
Ambulatory Research Center (ARC), Department of Psychiatry, Minneapolis
Uni of Chicago; Centre For Advanced Medicine, Chicago
St Louis Clinical Trials, St Louis
Louisiana Research Associates, New Orleans
Ips Research Company, Oklahoma City
FutureSearch Trials, LP, Austin
Excell Research, Oceanside
Stanford University School of Medicine, Stanford
Eastside Therapeutic Resource, Kirkland
Yale University School of Medicine; Neuroscience Research Training Program, New Haven
University of South Florida, Tampa
Massachusetts General Hospital - East, Boston
Boston Clinical Trials, Boston
Butler Hospital - Department of Psychiatry and Human Behavior, Providence
Chokka Center for Integrative Health, Edmonton
Okanagan Clinical Trials, Kelowna
True North Clinical Research-Halifax, Halifax
True North Clinical Research Kentville, Kentville
McMaster University - MacAnxiety Research Centre, Hamilton
Sunny Johnson Medical Research Associates Inc.; Medical Research Associates, Mississauga
START Clinic for Mood & Anxiety Disorders, Toronto
Hoffmann-La Roche
INDUSTRY